It is of note that recently a clinical trial was initiated in which CFI-402257 is being investigated as a single agent and in combination with fulvestrant in CDK4/6 inhibitor-resistant advanced estrogen receptor positive breast cancer associated with loss of the tumor suppressor, cell cycle regulator retinoblastoma (Rb) (NCT05251714). This evidence concerns the gene CDK4 and breast carcinoma.